APPEAL试验:冲击波碎石围手术期抗生素预防尿路感染的多中心随机对照研究
APPEAL为国际多中心盲法随机对照试验,将1722例接受冲击波碎石(SWL)的泌尿系结石成人随机分配至单剂环丙沙星或安慰剂组。分析人群1694例中,环丙沙星组菌尿或症状性尿路感染(UTI)复合终点发生20例(2.7%),安慰剂组30例(3.9%)(RR 0.68,95%CI 0.41-1.15);肾盂肾炎分别为0例与9例(1.2%)(RR 0.05,95%CI 0.003-0.93);无尿源性脓毒症及严重不良事件。单剂环丙沙星可降低SWL后肾盂肾炎风险,但绝对获益有限。
要点
- 单剂环丙沙星使SWL后肾盂肾炎风险显著降低(RR 0.05,95%CI 0.003-0.93)。
- 菌尿或症状性UTI复合终点及症状性UTI在两组间差异未达统计学显著性。
- 绝对获益有限,需结合个体偏好权衡抗生素潜在危害及耐药影响。
核心结论
- 单剂环丙沙星可降低SWL后肾盂肾炎风险,但绝对获益有限,其临床重要性取决于患者对小幅绝对风险下降与抗生素潜在危害及耐药影响的个体权衡。
研究设计与样本
- APPEAL为国际多中心、盲法随机对照试验,成人泌尿系结石SWL患者随机接受单剂环丙沙星或安慰剂。
- 共随机1722例,排除28例随机后剔除(主要为结石不可视),分析人群1694例;中位年龄50岁,女性占30%,肾结石74%、输尿管结石26%。
主要发现
- 菌尿(无症状)或症状性UTI复合终点:环丙沙星组20例(2.7%)vs 安慰剂组30例(3.9%),RR 0.68(95%CI 0.41-1.15)。
- 肾盂肾炎:环丙沙星组0例 vs 安慰剂组9例(1.2%),RR 0.05(95%CI 0.003-0.93)。
- 无患者发生尿源性脓毒症,无严重不良事件。
临床怎么用
- SWL围手术期可考虑单剂环丙沙星以降低肾盂肾炎风险,但需与患者共同决策,权衡小幅绝对获益与抗生素相关危害及耐药风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Shockwave lithotripsy (SWL) carries a risk of postprocedural infection. Use of antibiotic prophylaxis by clinicians is variable and international guidelines provide conflicting recommendations, reflecting low-certainty evidence. We investigated whether antibiotic prophylaxis reduces bacteriuria and post-SWL urinary tract infections (UTIs). METHODS: APPEAL, an international multicenter, blinded trial, randomized adults undergoing SWL for urolithiasis to a single dose of ciprofloxacin or placebo. The primary outcome was the incidence of a composite of bacteriuria or symptomatic UTI after SWL. Other outcomes included the incidence of pyelonephritis or urosepsis. KEY FINDINGS AND LIMITATIONS: Of the 1722 randomized patients, 28 underwent postrandomization exclusions (mainly nonvisualizable stones). Among the analysis population (n = 1694; median age 50 yr; 30% female), 74% had kidney stones and 26% had ureteral stones. Bacteriuria (without symptoms) or symptomatic UTI occurred in 20 patients (2.7%) in the ciprofloxacin arm and 30 (3.9%) in the placebo arm (risk ratio [RR] 0.68, 95% confidence interval [CI] 0.41-1.15). Symptomatic UTI occurred in ten patients (1.3%) in the ciprofloxacin arm and 21 (2.7%) in the placebo arm (RR 0.49, 95% CI 0.19-1.23). No patients in the ciprofloxacin arm and nine (1.2%) in the placebo arm developed pyelonephritis (RR 0.05, 95% CI 0.003-0.93). No patients developed urosepsis and no serious adverse events occurred. CONCLUSIONS AND CLINICAL IMPLICATIONS: A single dose of ciprofloxacin reduced the risk of post-SWL pyelonephritis, with a modest absolute benefit. The patient importance of this reduction depends on individual preferences in weighing a small absolute reduction in risk against the potential harms and resistance-related implications of antibiotic use. Results from the APPEAL trial will inform global practice and support evidence-based decision-making for patients undergoing SWL.
引用
- Tikkinen KAO, Najafabadi BT, Hajebrahimi S, et al. A Multicenter Randomized Controlled Trial of Antimicrobial Prophylaxis to Prevent Urinary Tract Infections after Shockwave Lithotripsy for Urolithiasis: The APPEAL Trial. Eur Urol. 2025. PMID: 40998628. doi:10.1016/j.eururo.2025.08.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。